Correction of DMD in human iPSC-derived cardiomyocytes by base-editing-induced exon skipping

Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene. Previously, we showed that adenine base ed-iting (ABE) can efficiently correct a nonsense point mutation in a DMD mouse model. Here, we explored the feasibility of base -editing-mediated exon skipping as a therapeutic strategy for DMD using cardiomyocytes derived from human induced pluripotent stem cells (hiPSCs). We first generated a DMD hiPSC line with a large deletion spanning exon 48 through 54 (DE48-54) using CRISPR-Cas9 gene editing. Dystrophin expression was disrupted in DMD hiPSC-derived cardiomyo-cytes (iCMs) as examined by RT-PCR, western blot, and immu-nofluorescence staining. Transfection of ABE and a guide RNA (gRNA) targeting the splice acceptor led to efficient conversion of AG to GG (35.9% +/- 5.7%) and enabled exon 55 skipping. Complete AG to GG conversion in a single clone restored dys-trophin expression (42.5% +/- 11% of wild type [WT]) in DMD iCMs. Moreover, we designed gRNAs to target the splice sites of exons 6, 7, 8, 43, 44, 46, and 53 in the mutational hotspots and demonstrated their efficiency to induce exon skipping in iCMs. These results highlight the great promise of ABE-medi-ated exon skipping as a promising therapeutic approach for DMD.

Automated summary

This study investigates the feasibility of base-editing-mediated exon skipping as a therapeutic strategy for Duchenne muscular dystrophy (DMD). The researchers successfully corrected gene mutations and induced exon skipping using adenine base editing (ABE) and guide RNA (gRNA) in DMD patient-derived cardiomyocytes, restoring dystrophin expression. These findings highlight the potential of ABE-mediated exon skipping as a promising therapeutic approach for DMD.